drugset / Trial / NCT00729833
Study Of CP-751,871 In Combination With Sunitinib In Patients With Advanced Solid Tumors
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The study is being conducted to determine the maximum tolerated dose, overall safety and tolerability profile, and pharmacokinetic profile of CP-751,871 and sunitinib when given in combination with advanced solid tumors.
Timeline
- Start
- 2008-09
- Primary completion
- 2011-08
- Completion
- 2013-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Figitumumab | Monoclonal antibody | — | Intravenous |
| Subject | Sunitinib | Small molecule | — | — |